Table 3.

Predictors of ATTR-CA among elderly patients undergoing TAVR

	N	OR	95% CI	C-statistic	P-value
Univariable
Age, per 1 year increase	151	1.09	(1.01–1.18)	0.635	0.034
Gender, male vs. female	151	6.46	(1.45–28.72)	0.643	0.014
Modified BMI, per 1 kg·dL/m2·g increase	151	0.98	(0.96–1.00)	0.603	0.085
Coronary artery disease, yes vs. no	151	1.89	(0.70–5.08)	0.568	0.210
Elevated BNPa, yes vs. no	119	2.96	(1.07–8.19)	0.627	0.037
Systolic blood pressure, per 1 mmHg increase	151	1.00	(0.98–1.02)	0.466	0.893
QRS duration, per 1 ms increase	142	1.02	(1.01–1.03)	0.672	0.021
Albumin, per 1 g/dL increase	151	0.55	(0.22–1.36)	0.597	0.195
Mean gradient, per 1 mmHg increase	148	0.97	(0.93–1.00)	0.617	0.061
LVEF, per 1% decrease	151	1.04	(1.01–1.06)	0.640	0.014
LA dimension, per 1 mm increase	141	1.10	(1.03–1.17)	0.702	0.003
IVSD ≥1.2 vs. <1.2 cm	147	4.10	(1.52–11.03)	0.664	0.005
SV index <35 vs. ≥35 mL/m2	147	4.53	(1.68–12.21)	0.676	0.003
Severe symptomatic AS stage				0.605	0.058
Stage D2 vs. D1	148	3.66	(1.26–10.64)		0.017
Stage D3 vs. D1	148	1.51	(0.30–7.68)		0.619
MCF, per 1 unit decrease	147	1.10	(1.05–1.15)	0.789	<0.0001
Average mitral annular S’, per 1 cm/s decrease	136	5.0	(2.56–9.09)	0.947	<0.0001
E/A ratio, per 1 unit increase	136	2.08	(1.39–3.11)	0.719	0.0004
Model selection: ‘final’ modelb
Average mitral annular S’, per 1 cm/s decrease	136	5.0	(2.56–9.09)	0.719	<0.0001

ATTR-CA, transthyretin cardiac amyloidosis; TAVR, transcatheter aortic valve replacement; OR, odds ratio; CI, confidence interval; BNP, brain natriuretic peptide; BMI, body mass index; LVEF, left ventricular ejection fraction; LA, left atrium; AS, aortic stenosis; IVSD, interventricular septum at diastole.

^aElevated BNP was designated for patients if BNP ≥300 pg/mL or NT proBNP ≥2000 pg/mL.

^bThe ‘final’ model shows the unanimous recommendations of several model building strategies (backward, forward, and stepwise) that considered all non-collinear predictors with P < 0.25 from univariable regression.